Schering Plough’s Antipsychotic Saphris To Face FDA Panel Review In July
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Psychopharmacologic Drugs panel will likely consider supplemental data Schering submitted in response to an FDA complete response letter issued in January.
You may also be interested in...
Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review
Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.
Schering's Antipsychotic Saphris Should Have Easy Advisory Committee Review
Label for asenapine could be highly favorable on weight and adverse event issues given FDA's enthusiasm.
Vanda’s Fanapt Approval Shows Evolution Of FDA’s Thinking
FDA's approval of Vanda's Fanapt (iloperidone) May 6 means that the bar for new atypical antipsychotic approvals may not be as high as it seemed 10 months ago, when FDA's "not approvable" letter on iloperidone requested an additional comparative trial